Propeller Health is to enter into to a research and development collaboration with pharmaceutical manufacturer GlaxoSmithKline to test a custom sensor for the companies Ellipta inhaler for COPD. GSK will conduct a number of studies of patients with COPD, monitoring the patient's adherence remotely with help from the sensors, which will provide greater insights into how patients interact with their inhalers, and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes. Dave Allen, Senior Vice President of Respiratory R&D at GSK, said, "We continue to find new and better ways to conduct clinical trials by exploring novel patient centered outcomes through strategic collaborations. The company has also announced that it plans on developing an app called Propel's Smart Patient Experience (SPE) in partnership with the University of California, San Francisco (UCSF)
Propeller Health is to enter into to a research and development collaboration with pharmaceutical manufacturer GlaxoSmithKline to test a custom sensor for the companies Ellipta inhaler for COPD. GSK will conduct a number of studies of patients with COPD, monitoring the patient's adherence remotely with help from the sensors, which will provide greater insights into how patients interact with their inhalers, and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes. The company has also announced that it plans on developing an app called Propel's Smart Patient Experience (SPE) in partnership with the University of California, San Francisco (UCSF)